blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2519538

EP2519538 - CYCLOSPORINE ANALOGUES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  02.08.2013
Database last updated on 25.09.2024
Most recent event   Tooltip02.08.2013Change or deletion - application deemed withdrawnpublished on 04.09.2013  [2013/36]
Applicant(s)For all designated states
Scynexis, Inc.
Post Office Box 12878 Research Triangle Park
NC 27709-2878 / US
[2012/45]
Inventor(s)01 / OGBU, Cyprian, Okwara
Post Office Box 12878
Research Triangle Park NC 27709-2878 / US
02 / RICHARDSON, Thomas, Edward
Post Office Box 12878
Research Triangle Park NC 27709-2878 / US
 [2012/45]
Representative(s)Jump, Timothy John Simon, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[2012/45]
Application number, filing date10799265.330.12.2010
WO2010US62480
Priority number, dateUS20090290917P30.12.2009         Original published format: US 290917 P
[2012/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011082289
Date:07.07.2011
Language:EN
[2011/27]
Type: A1 Application with search report 
No.:EP2519538
Date:07.11.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 07.07.2011 takes the place of the publication of the European patent application.
[2012/45]
Search report(s)International search report - published on:EP07.07.2011
ClassificationIPC:C07K7/64, A61P31/12
[2012/45]
CPC:
C07K7/645 (EP,US); C07K7/64 (KR); A61K38/13 (KR);
A61P31/12 (EP); A61P31/14 (EP); A61K38/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/45]
TitleGerman:CYCLOSPORIN-ANALOGA[2012/45]
English:CYCLOSPORINE ANALOGUES[2012/45]
French:ANALOGUES DE CYCLOSPORINE[2012/45]
Entry into regional phase11.07.2012National basic fee paid 
11.07.2012Designation fee(s) paid 
11.07.2012Examination fee paid 
Examination procedure11.07.2012Examination requested  [2012/45]
05.10.2012Application deemed to be withdrawn, date of legal effect  [2013/34]
05.03.2013Application deemed to be withdrawn, date of legal effect  [2013/36]
05.03.2013Loss of particular rights, legal effect: Claims
08.04.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2013/36]
08.04.2013Despatch of communication of loss of particular rights: Claims {1}
Fees paidPenalty fee
Additional fee for renewal fee
31.12.201203   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[YD]WO9849193  (RHONE POULENC RORER SA [FR], et al) [YD] 1-16 * page 35, line 9 - page 41, line 15; examples 3,6, 7; claims 1,6,8 *;
 [YD]US5948884  (LUECHINGER JEAN MARTIN [CH]) [YD] 1-16 * examples 1-3 *;
 [YP]WO2010076329  (SCYNEXIS INC [US], et al) [YP] 1-16 * claim 1 *;
 [Y]WO2007049803  (ASTELLAS PHARMA INC [JP], et al) [Y] 1-16 * examples 16, 25, 28, 29, 32, 33, 35, 52, 57, 67-69, 81, 82; claims 1-4,14 *;
 [YP]WO2010088573  (ENANTA PHARM INC [US], et al) [YP] 1-16 * claims 1-6, 9 *
by applicantEP0484281
 US5948755
 US5994299
 US5948884
 US6583265
 WO2006039668
 WO2007041631
 US7196161
 WO9849193
 US5977067
 WO9932512
 WO9967280
 US3845770
 US3916899
 US3536809
 US3598123
 US4008719
 US5674533
 US5059595
 US5591767
 US5120548
 US5073543
 US5639476
 US5354556
 US5639480
 US5733566
 US5739108
 US5891474
 US5922356
 US5972891
 US5980945
 US5993855
 US6045830
 US6087324
 US6113943
 US6197350
 US6248363
 US6264970
 US6267981
 US6376461
 US6419961
 US6589548
 US6613358
 US6699500
 US6630343
    - WATASHI ET AL., HEPATOLOGY, (2003), vol. 38, pages 1282 - 1288
    - NAKAGAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (2004), vol. 313, pages 42 - 7
    - AMERICAN JOURNAL OF TRANSPLANTATION, (2004), vol. 4, no. S8, pages 1 - 653
    - CARRY, SYNLETT, (2004), vol. 2, pages 316 - 320
    - RUEGGER ET AL., HELV. CHIM. ACTA., (1976), vol. 59, pages 1075 - 92
    - BOREL ET AL., IMMUNOLOGY, (1977), vol. 32, pages 1017 - 25
    - "Cyclosporins: Recent Developments in Biosynthesis, Pharmacology and Biology, and Clinical Applications", J. KALLEN ET AL., Biotechnology, (1997), pages 535 - 591
    - CAHN ET AL., ANGEW. CHEM., (1966), vol. 78, pages 413 - 447
    - ANGEW. CHEM., INT. ED. ENGL., vol. 5, pages 385 - 414
    - ANGEW. CHEM., INT. ED. ENGL., vol. 5, page 511
    - PRELOG; HELMCHEN, ANGEW. CHEM., (1982), vol. 94, pages 614 - 631
    - ANGEW. CHEM. INTERNAT. ED. ENG., vol. 21, pages 567 - 583
    - MATA; LOBO, TETRAHEDRON: ASYMMETRY, (1993), vol. 4, pages 657 - 668
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, (1995), pages 379 - 80
    - CRC CRIT. REF BIOMED. ENG., (1987), vol. 14, page 201
    - BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507
    - SAUDEK ET AL., N. ENGL. J. MED., (1989), vol. 321, page 574
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - SIMMONDS, J GEN VIROL., (2004), vol. 85, pages 3173 - 88
    - SIMMONDS, J. GEN. VIROL., (2001), vol. 82, pages 693 - 712
    - MAIER; WU, WORLD J GASTROENTEROL, (2002), vol. 8, pages 577 - 57
    - LESENS ET AL., J INFECT DIS, (1999), vol. 179, pages 1254 - 1258
    - LINNANEN ET AL., JOURNAL OFMEDICINAL. CHEMISTRY, (2000), vol. 43, page 1339
    - KRIGER, JOURNAL OF VIROLOGY, (2001), vol. 75, pages 4614 - 4624
    - PIETSCHMANN, JOURNAL OF VIROLOGY, (2002), vol. 76, pages 4008 - 4021
    - WEISLOW ET AL., J. NATL. CANCER INST., (1989), vol. 81, pages 577 - 586
    - QUESNIAUX ET AL., EUR. J IMMUNOL., (1987), vol. 17, pages 1359 - 1365
    - BLATTNER ET AL., ANALYTICAL BIOCHEM, (2001), vol. 295, page 220
 US20170612909
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.